<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275092</url>
  </required_header>
  <id_info>
    <org_study_id>CorPath PRECISE</org_study_id>
    <nct_id>NCT01275092</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)</brief_title>
  <acronym>PRECISE</acronym>
  <official_title>CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corindus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corindus Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of the clinical and
      technical performance of the CorPath® 200 System in the delivery and manipulation of coronary
      guidewires and stent/balloon systems for use in percutaneous coronary interventions (PCI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Clinical Procedural Success</measure>
    <time_frame>48-hrs or hospital discharge, whichever occurs first</time_frame>
    <description>Defined as &lt;30% residual stenosis in CorPath 200 System treated lesions at the completion of the interventional procedure (including stent placement) in the absence of MACE, either within 48 hours of the procedure or prior to hospital discharge, whichever occurs first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With Device Technical Success</measure>
    <time_frame>1 day</time_frame>
    <description>Defined as the successful advancement and retraction of PCI devices using the CorPath 200 System and without conversion to manual operation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Ratio Between the Radiation Exposure of the Primary Operator and the Radiation Exposure at the Table</measure>
    <time_frame>1 day</time_frame>
    <description>Defined as the difference between the radiation exposure measured at the procedure table (the conventional site of the primary operator) and the radiation exposure measured at the primary operator's position during the procedure. The radiation unit that was used was in milligray, but the measure is being reported as the ratio.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>CorPath robotic-assisted PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CorPath 200 robotic-assisted PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CorPath robotic-assisted PCI</intervention_name>
    <description>CorPath 200® robotic-assisted percutaneous coronary intervention</description>
    <arm_group_label>CorPath robotic-assisted PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          1. Subject is between 18 and 99 years of age.

          2. Subject is an acceptable candidate for PCI.

          3. Subject must have clinical evidence of ischemic heart disease or a positive functional
             study.

          4. Female subjects must be of non-child bearing potential, or if able to bear children,
             have a negative pregnancy test within 7 days prior to the CorPath procedure.

          5. The subject or the legal representative has been informed of the nature of the study
             and agrees to its provisions and has provided written informed consent.

        Angiographic Inclusion Criteria:

          1. Study lesion is a single de novo native coronary artery lesion. This lesion may
             consist of multiple lesions (with 10mm or less between diseased segments) and must be
             completely covered by a single stent with at least 2.0mm of normal segments on
             proximal and distal edges of the lesion.

          2. Study reference vessel diameter is between 2.5mm and 4.0mm by visual estimate.

          3. Study lesion length is less than or equal to 24.0mm by visual estimate.

          4. Study lesion diameter showing stenosis of at least 50% by visual estimate.

        General Exclusion Criteria:

          1. Subject requires planned PCI or CABG (Coronary Artery Bypass Graft) within 30 days
             following the CorPath procedure.

          2. Evidence of an acute myocardial infarction within 72 hours prior to the intended
             CorPath procedure.

          3. Subject has documented left ventricular ejection fraction &lt;30%.

          4. Subject has undergone PCI within 72 hours prior to the CorPath procedure.

          5. Subject has undergone PCI within 30 days prior to the CorPath procedure and
             experienced a major adverse coronary event (MACE) or a serious adverse event (SAE) as
             defined in the protocol.

          6. Subject has known hypersensitivity or contraindication to aspirin, heparin,
             ticlopidine, clopidogrel, prasugrel, stainless steel, cobalt chromium, or sensitivity
             to contrast media, including Visipaque™, which cannot be adequately pre-medicated or
             managed with clinically appropriate substitutes.

          7. Subject has a platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3, or a WBC (white
             blood cell) count of &lt;3,000 cells/mm3 (e.g. thrombocytopenia, thrombocythemia,
             neutropenia or leukopenia).

          8. Subject has a serum creatinine level of &gt;2.0 mg/dL or eGFR (estimated Glomerular
             Filtration Rate) &lt;30 ml/min as measured within 7 days prior to the procedure.

          9. Subject has suffered a stroke within 30 days prior to planned CorPath procedure.

         10. Subject has an active peptic ulcer or upper gastrointestinal bleeding within the 6
             months prior to planned CorPath procedure.

         11. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions.

         12. Subject is currently participating in another investigational drug or drug/device or
             device trial and has not completed the entire follow up period.

         13. Femoral access is not possible.

        Angiographic Exclusion Criteria:

          1. Target lesion that cannot be fully covered by a single stent.

          2. Subject requires treatment of more than one vessel.

          3. Any previous stent placement within 5.0 mm (proximal or distal) of the target lesion.

          4. The study lesion requires planned treatment with directional coronary atherectomy
             (DCA), laser, rotational atherectomy or any device except for balloon dilatation prior
             to stent placement.

          5. The study vessel has evidence of intraluminal thrombus.

          6. The study vessel has evidence of moderate to severe tortuosity (&gt;90°) proximal to the
             target lesion.

          7. The study lesion has any of the following characteristics:

               -  Total occlusion.

               -  Ostial location.

               -  Is within 2.0 mm of a side branch measuring &gt;2.0 mm in diameter.

               -  Located at &lt; 45° bend in the vessel.

               -  Moderately to severely calcified.

               -  Moderate to severe calcification in the vessel proximal to the target lesion.

               -  Located in a native vessel distal to an anastomosis, with a saphenous vein graft
                  or a left/right internal mammary artery (LIMA/RIMA) bypass, and is approached
                  through the bypass graft.

          8. Unprotected left main coronary artery disease defined as an obstruction greater than
             50% diameter stenosis in the left main coronary artery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michail Pankratov, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Corindus Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Heart Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CORBIC</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.corindus.com</url>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <results_first_submitted>August 9, 2012</results_first_submitted>
  <results_first_submitted_qc>August 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2013</results_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>robotic-assisted PCI</keyword>
  <keyword>coronary intervention</keyword>
  <keyword>CorPath PRECISE</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>During January-December 2011 period 164 participants were enrolled in the PRECISE study at 9 clinical sites</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CorPath Robotic-assisted PCI</title>
          <description>CorPath 200 robotic-assisted PCI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CorPath Robotic-assisted PCI</title>
          <description>CorPath 200 robotic-assisted PCI</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Clinical Procedural Success</title>
        <description>Defined as &lt;30% residual stenosis in CorPath 200 System treated lesions at the completion of the interventional procedure (including stent placement) in the absence of MACE, either within 48 hours of the procedure or prior to hospital discharge, whichever occurs first.</description>
        <time_frame>48-hrs or hospital discharge, whichever occurs first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CorPath Robotic-assisted PCI</title>
            <description>CorPath 200 robotic-assisted PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Procedural Success</title>
          <description>Defined as &lt;30% residual stenosis in CorPath 200 System treated lesions at the completion of the interventional procedure (including stent placement) in the absence of MACE, either within 48 hours of the procedure or prior to hospital discharge, whichever occurs first.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="94.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Device Technical Success</title>
        <description>Defined as the successful advancement and retraction of PCI devices using the CorPath 200 System and without conversion to manual operation.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CorPath Robotic-assisted PCI</title>
            <description>CorPath 200 robotic-assisted PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Device Technical Success</title>
          <description>Defined as the successful advancement and retraction of PCI devices using the CorPath 200 System and without conversion to manual operation.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="96.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Ratio Between the Radiation Exposure of the Primary Operator and the Radiation Exposure at the Table</title>
        <description>Defined as the difference between the radiation exposure measured at the procedure table (the conventional site of the primary operator) and the radiation exposure measured at the primary operator's position during the procedure. The radiation unit that was used was in milligray, but the measure is being reported as the ratio.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CorPath Robotic-assisted PCI</title>
            <description>CorPath 200 robotic-assisted PCI</description>
          </group>
        </group_list>
        <measure>
          <title>The Ratio Between the Radiation Exposure of the Primary Operator and the Radiation Exposure at the Table</title>
          <description>Defined as the difference between the radiation exposure measured at the procedure table (the conventional site of the primary operator) and the radiation exposure measured at the primary operator's position during the procedure. The radiation unit that was used was in milligray, but the measure is being reported as the ratio.</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CorPath Robotic-assisted PCI</title>
          <description>CorPath 200 robotic-assisted PCI</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Others</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cardiovascular complications</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Others</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular complications</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Giora Weisz, MD; Director of Clinical Resarch Center for Interven tional Vascular Therapy</name_or_title>
      <organization>Columbia University Medical Center, New York, NY, 10032</organization>
      <phone>212-305-7060</phone>
      <email>gweisz@crf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

